“GLP-1s Explained: Benefits, Risks, and What Doctors Don’t Tell You” Dr. Eric Westman (feat. Pathologist guest commentary)
This article is a summary of a video by Dr. Eric Westman, in which he reacts to commentary from a pathologist on the biology, benefits, risks, and safe use of GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound. You can watch the original video here.
This article is for information purposes only and does not constitute medical advice. Please speak to your healthcare professional before starting any medication.
[INTRO – Dr. Eric Westman]
A pathologist is warning about the biological cost of GLP-1 medications — Ozempic, Wegovy, Zepbound, and Mounjaro. But what does that mean inside the body? Let’s unpack the science.
Hi, I’m Dr. Eric Westman, and welcome to my channel where I review and debunk nutritional misinformation online. In this video, we’re going to hear a very scholarly view of the history of the new weight loss shots, where they come from, and how to optimize them — at least from one doctor’s perspective. Be sure to wait until the end for my final thoughts.
[THE PATHOLOGIST – On Why Miracles Don’t Exist in Medicine]
In 2024, humanity discovered something extraordinary — a weekly injection that could quiet hunger, stabilize blood sugar, and melt weight faster than anything medicine had seen. Headlines called it the end of obesity, the billion-dollar miracle, the cure. But I’m a pathologist, and in my world, miracles don’t really exist in this setting. There are always mechanisms behind everything. Anytime you override a biological system that took two million years to evolve, you are making a trade. And every trade has an invoice — a cost to pay and a receipt.
Right now, the public conversation around GLP-1 medications (known commercially as Ozempic and Mounjaro) is chaotic. Half promise salvation and half warn of disaster. Very few explain the biology. So today we’re going to fix that.
This is your evidence-based, mechanism-first understanding of GLP-1 drugs: how they work, why they work, why they sometimes backfire, and how to use them safely. We’ll walk through the evolutionary trap behind modern obesity, the “lizard brain” that controls hunger, the Gila Monster discovery that changed medicine, the engineering behind 7-day appetite suppression, the benefits, the trade-offs, the real-world risks, and the safe, medically aligned exit strategy. This is not fear. This is not hype. It’s purely physiology.
[WHY LOSING WEIGHT IS BIOLOGICALLY DIFFICULT]
THE PATHOLOGIST – Let me start with a truth almost no one hears from their doctor. Obesity is not a moral failure. It’s an evolutionary success. For 99.9% of human history, starvation — not overeating — was the number one cause of death. Anthropologists writing in the Journal of Human Evolution describe how hunger shaped early human survival. The people who could store fat most efficiently survived. Those who burned through calories quickly didn’t. So you are the descendants of the world’s best fat storers.
DR. WESTMAN – I like that description. He led off with “it’s not your fault” — and you need to hear that if you’re looking to lose weight or reverse diabetes. Knowing the physiology makes you realize it really is just biology.
[HOW GLP-1 WORKS IN THE BODY]
THE PATHOLOGIST – Intestinal cells called L-cells release a hormone called GLP-1. GLP-1 does three things immediately: it prepares the pancreas for insulin, it slows the stomach, and it tells the brain we’re satisfied. This is called the incretin effect, first described in the Journal of Clinical Investigation. But natural GLP-1 breaks down in just two minutes because of an enzyme called DPP-4. If scientists wanted to use GLP-1 as a drug, they needed to outsmart DPP-4.
The breakthrough came from a creature most people have never heard of — the Gila Monster. In the desert, there is a venomous lizard that eats only a few times a year. A researcher named Dr. John Eng discovered that its venom contains a molecule called exendin-4, described in Endocrinology in 1992. Exendin-4 acts like GLP-1 and binds the same receptor, but doesn’t break down quickly. It doesn’t get sliced apart by DPP-4. It survives. This was the blueprint for the first GLP-1 medications. But modern scientists took this idea and engineered something far more powerful — a hormone that can survive for seven days.
DR. WESTMAN – So in other words, when you eat, GLP-1 is released and helps you feel full. When you take the shot, your body is being tricked into thinking you’ve already eaten. Our normal GLP-1 only lasts a few hours, but what you’re injecting has been modified so it lasts much longer.
[THE ENGINEERING OF SEMAGLUTIDE]
THE PATHOLOGIST – Semaglutide (the molecule in Ozempic and Wegovy) is a triumph of modern chemistry. Researchers wanted something that behaved like
natural GLP-1 but lasted long enough to be effective as a weekly therapy. They did two brilliant things, discussed in Nature Biology in 2017. First, they changed one amino acid. This prevents DPP-4 from cutting the molecule. Second, they attached a C18 fatty acid tail. This tail binds to albumin, a massive protein circulating in your blood for about a week. Albumin acts like a cruise ship; semaglutide attaches to it and travels through your bloodstream for days. A hormone that should last only two minutes now lasts 168 hours. This one modification changed the landscape of metabolic medicine.
DR. WESTMAN – The story of the Gila Monster is one most doctors don’t even know; and it’s a good one.
[THE UPGRADE — TIRZEPATIDE (MOUNJARO / ZEPBOUND)]
THE PATHOLOGIST – Then came the upgrade. Tirzepatide (known as Mounjaro and Zepbound) doesn’t activate just one receptor; it activates two: GLP-1 and GIP. The dual action was first described in the New England Journal of Medicine in 2022, comparing tirzepatide to semaglutide. When combined, GLP-1 quiets appetite while GIP stabilizes nausea and enhances glucose control. This synergy allows for deeper appetite reduction with potentially better tolerance for many patients. This is why tirzepatide often leads to greater average weight loss than semaglutide in clinical trials, though individual results vary.
DR. WESTMAN – In the clinic where I work, the one you can get least expensively (or that insurance covers) is probably the appropriate choice at the moment. The second-generation shots, Zepbound and Mounjaro, do show a little extra benefit in head-to-head trials, but at $500 a month for many people, that’s a real downside. At the last obesity medicine conference I attended, there are already third-, fourth-, and fifth-generation shots in development. There are even pills now that mimic the effect of the shots. This is just the beginning.
[THE TRADE-OFFS AND RISKS – Stomach Slowing and Nausea]
THE PATHOLOGIST – GLP-1 medications work in part by slowing stomach emptying; something documented extensively in gastroenterology research, including Clinical Gastroenterology and Hepatology in 2023. For many people, this effect is mild and therapeutic. It keeps food in the stomach longer, reducing appetite. But for a subset of individuals, especially at higher doses, this delay can become more pronounced. Some people experience nausea, reflux, bloating, early fullness, and slower digestion. Most of the time these symptoms are manageable and often improve with dose adjustment.
DR. WESTMAN – In clinical trials, roughly a third of people dropped out because of nausea and stomach issues. In clinical practice, what doctors have learned is to use a medication that counters the nausea. You might need an anti-nausea pill for a day or two right after the shot. Don’t suffer through it. Two-thirds of people in clinical trials and in clinical practice do just fine without severe nausea.
[THE TRADE-OFFS AND RISKS – Gastroparesis]
THE PATHOLOGIST – In rare cases, the slowing can be significant enough that clinicians evaluate for delayed gastric emptying; sometimes called gastroparesis. Case reports published in GI literature describe a small number of patients developing more severe symptoms: persistent bloating, vomiting, and difficulty handling solid meals. It’s rare, but it’s real.
DR. WESTMAN – With severe gastroparesis, you might feel full or nauseated all the time, and you might not be able to eat or drink much. If you haven’t been able to consume anything (including liquids) in a few days, consult your doctor or urgent care. I wouldn’t say it’s rare because we’ve all seen it in practice. It’s not common, but many people say it’s still worth it.
[THE TRADE-OFFS AND RISKS – The Anesthesia Problem]
THE PATHOLOGIST – There’s something patients don’t hear until the day of surgery, namely the the anesthesia problem. If your stomach empties more slowly than usual, you may have residual food in your stomach even after fasting. This matters because anesthesia turns off the protective airway reflexes. If vomiting occurs while sedated, stomach contents can enter the lungs. Anesthesiologists call this aspiration. Because of this, the American Society of Anesthesiologists in 2023 issued updated guidelines recommending special precautions for patients on GLP-1 medications before surgery. This doesn’t mean anesthesia is unsafe, but your anesthesiologist needs to know you’re on these medications. Awareness is prevention.
DR. WESTMAN – If you have elective surgery, stop the GLP-1 in advance and talk to your anesthesiologist. If it’s emergency surgery, make sure your physician knows. Aspiration (inhaling stomach contents into the lungs) can cause pneumonia and serious complications, even with simple operations.
[THE TRADE-OFFS AND RISKS – Pancreatitis]
THE PATHOLOGIST – There have been reports of pancreatitis (inflammation of the pancreas) in people taking GLP-1 medications. Large clinical trials, including those published in Gastroenterology in 2022, show that the overall risk appears low. But the prescribing information includes cautions for good reason. People with a history of pancreatitis, very high triglycerides, or heavy alcohol use already carry a baseline risk for pancreatic inflammation; clinicians use extra caution for these individuals. Most patients will never experience this issue. But if someone on these medications develops persistent, severe abdominal pain, that is something a physician should evaluate.
DR. WESTMAN – It’s important to note that issues like the anesthesia aspiration risk only became apparent after these medications were widely released. We’re still learning. When a medicine is released at this scale, new issues arise that we become aware of over time.
[THE TRADE-OFFS AND RISKS – Muscle Loss]
THE PATHOLOGIST – When you lose weight quickly from any method, you lose both fat and muscle. On GLP-1 medications, appetite drops dramatically, protein intake often decreases, strength training becomes harder, and nausea can reduce food variety. Emerging studies (including those in the Obesity Journal in 2023) show that without deliberate nutritional and resistance training support, some patients lose a meaningful percentage of lean mass.
DR. WESTMAN – This is the Achilles heel of rapid weight loss, even weight loss surgery. You lose muscle because you’re losing so fast and can’t get enough protein in. If you’re not eating at all, contact your doctor; that’s one guardrail you really don’t want to cross.
[THE TRADE-OFFS AND RISKS – “Ozempic Face”]
THE PATHOLOGIST – There’s a lot of buzz about “Ozempic face.” In truth: it’s not the drug damaging the skin, it’s rapid fat loss. When fat pads in the face shrink quickly, the skin doesn’t always retract at the same pace. Plastic surgeons and dermatologists, including those publishing in the Aesthetic Surgery Journal in 2024, describe this as a simple volume change. It’s not a toxicity reaction. Slower, steadier weight loss preserves facial structure better. Strength training and adequate protein intake help too.
[THE TRADE-OFFS AND RISKS – Mood and Dopamine Effects]
THE PATHOLOGIST – Some people describe feeling less impulsive, less interested in food, calmer, and more stable. And for many this is a genuine benefit. But a subset describe something different: less motivation, muted joy, a grayscale feeling, lower reward drive. It’s not sadness, it’s not quite depression; just a reduced spark. Pre-clinical research in Translational Psychiatry published in 2024 and ongoing human studies suggest GLP-1 receptors in the reward pathways (including the nucleus accumbens) may modulate dopamine signaling. Not in everyone, and not dramatically in most, but enough for people to notice. This is why monitoring your mental and emotional landscape is important while on these medications. If you feel flatter than expected, your clinician probably wants to know.
DR. WESTMAN – I remember a patient on a GLP-1 who said food just wasn’t tasty anymore. For her, that was a real downside as food was one of the most important parts of her family culture. Not having the pleasure or desire for food can be quite profound.
[WEIGHT REGAIN AFTER STOPPING]
THE PATHOLOGIST – Now we arrive at the question everyone asks: if I stop Ozempic or Mounjaro, will I gain the weight back? The most evidence-aligned answer is: many people regain weight without a strategy. Not because they failed, but because biology rebounds. In the STEP 1 extension trial published in the New England Journal of Medicine in 2022, participants regained roughly two-thirds of the weight they lost within 12 months of stopping, unless they had robust lifestyle support.
Here’s why this happens. First, hunger hormones surge back. While on GLP-1 medications, ghrelin (your hunger hormone) is suppressed. When the medication leaves your system, ghrelin doesn’t return to baseline; it overshoots. This is well documented in metabolic studies published in Endocrine Reviews in 2021. Second, appetite returns faster than satiety signals reach the brain. The hypothalamus regains sensitivity before the gut does — that mismatch creates a transient hyper-hunger period. Third, muscle mass has decreased. Less muscle means a slower metabolic rate. When appetite returns, the engine is smaller, and fat accumulates faster than muscle rebuilds. This is called preferential adipose regain, demonstrated in the Metabolism Journal in 2019.
DR. WESTMAN – Fat comes back when you eat fattening foods such as foods high in carbohydrates and sugar. You’ll want to transition to a low-carb or keto-type eating plan. During GLP-1 treatment, prioritize protein, do some resistance training, and then move toward a way of eating that keeps insulin low.
[THE FIVE PROTOCOLS FOR SAFE USE AND EXIT]
THE PATHOLOGIST – These protocols are based on peer-reviewed literature from journals like Sports Medicine, Cell Metabolism, and Nutrition Reviews. Always discuss with your personal physician first.
Rule 1: The Protein Floor
When appetite is low, protein is the first thing to disappear; but it is the last thing your body wants to lose. Aim for adequate daily protein intake; your clinician should guide your specific target. If solid food feels heavy, alternatives include clear whey isolate, collagen, essential amino acids, dairy proteins, and egg white proteins. Leucine and other amino acids directly signal muscle to stay intact. Protein is your muscle insurance, and muscle is your metabolic insurance.
DR. WESTMAN – I’ve seen patients so appetite-suppressed they eat nothing at all; that violates the protein floor. If you’re that suppressed, ask to have your dose adjusted or consider a different approach altogether.
Rule 2: Strength Training Is Mandatory
There is no drug, supplement, or hack that can replace mechanical load on muscle. Resistance training two to four days per week (squats, deadlifts, rows, presses, and pulls) signals the body: don’t break down this tissue, we need it. Studies in Sports Medicine in 2023 show that even two days per week can drastically reduce lean mass loss during weight loss.
DR. WESTMAN – Many patients I see cannot exercise at all. They’re too tired or their joints hurt too much. Still do what you can. If resistance training isn’t possible, consider a complementary approach like a low-carb or keto diet to support muscle preservation.
Rule 3: Taper Slowly
Do not stop GLP-1 medications abruptly. A sudden drop in GLP-1 signaling creates a rapid rebound in appetite. A gradual taper allows hunger hormones to recalibrate, satiety signals to normalize, your routine to strengthen, your muscles to grow, and your metabolism to stabilize. This aligns with physiology described in Endocrinology and Metabolism Clinics in 2022.
DR. WESTMAN – In practice, insurance coverage changes can force people on and off these medications without warning. One of the most important things you can do is change your diet while you’re still on the medication — so that if you ever have to stop, you have another way to maintain your results.
Rule 4: Use Fiber as a Mechanical Satiety Tool
Once medication doses decrease, your stomach begins sending hunger signals again. To bridge this gap, use high-volume, low-calorie foods that stretch the stomach’s mechanical receptors — oats, beans, berries, vegetables, lentils, and psyllium husk. This is backed by satiety research published in Appetite Journal in 2020.
DR. WESTMAN – If you’re following a low-carb approach, note that many of these foods are high in carbohydrates. Work with someone trained in obesity medicine who can help you tailor this to your individual response in real time.
Rule 5: Monitor Mood, Motivation, and Joy
GLP-1 receptors exist in the reward pathways of the brain. If your motivation drops, you lose interest in hobbies, or life feels flatter, speak with your physician. Studies in Translational Psychiatry in 2024 are actively exploring this finding. It may be dose-related, transient, or may require adjustment. Your emotional landscape is as important as your metabolic one.
[FINAL THOUGHTS – Dr. Eric Westman]
If you’ve never used a weight loss medication or been in a medically supervised program, you might think these shots are the only option available. But before there were shots, there were pills. Before pills, there were diets. It may be that this is the entry point that gets you into the weight loss world, but it doesn’t mean you have to feel bad while losing weight, and it doesn’t mean there aren’t alternative methods that work without the same biological costs.
GLP-1 medications have taught us something profound: obesity is biology, not a moral issue. For many, these medications reduce cardiovascular risk, improve metabolic health, stabilize blood sugar, calm obsessive food thoughts, and break cycles that have lasted for decades. For others, they are a bridge. A tool that helps build new habits while biology stabilizes. And for some, there are real trade-offs that require careful navigation.
There is no one-size-fits-all answer. There is only informed consent, evidence-based decision-making, and respect for the complexity of the human body. You’re not weak. You’re not broken. You’re not a moral failure. You’re a human being living in an environment your biology was never designed for. And now you have a powerful tool. Pair it with a protocol that honors your physiology.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any new dietary
